NeoPharm CO., LTD. (KOSDAQ: 092730)

Market Cap	182.61B
Revenue (ttm)	107.86B
Net Income (ttm)	22.93B
Shares Out	7.82M
EPS (ttm)	2,931.99
PE Ratio	7.96
Forward PE	7.22
Dividend	750.00 (3.23%)
Ex-Dividend Date	n/a

Volume	106,812
Open	23,300
Previous Close	23,200
Day's Range	23,100 - 24,000
52-Week Range	20,150 - 34,300
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 1, 2024

About NeoPharm CO., LTD.

NeoPharm CO., LTD. engages in the manufacturing and sale of skin care products in South Korea. The company provides Atopalm, a non-steroid product for sensitive and dry skin; skin dermo-cosmetic products under the Real Barrier brand name; sensitive, dry, oily, or trouble-prone skin care products under the ZEROID brand; body moisturizers under the Derma-B brand name; sport care products under the MISSION ATHELETCARE brand; and dermArtlogy, a 1:1 consulting cosmetic brand. NeoPharm CO., LTD. was founded in 2000 and is headquartered in Daejeon, So...

• Industry: Pharmaceutical Preparations
• Founded: 2000
• Employees: 172
• Stock Exchange: KOSDAQ
• Ticker Symbol: 092730

Financial Performance

In 2023, NeoPharm CO., LTD.'s revenue was 97.10 billion, an increase of 14.20% compared to the previous year's 85.03 billion. Earnings were 23.21 billion, an increase of 36.33%.